This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ₹2,020.30, up by ₹0.85, or 0.042%, on the BSE.
This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ₹2,020.30, up by ₹0.85, or 0.042%, on the BSE.